RE: RE: Mcc Abstract to be presented May 22 2012 Re: post I just made...one point I should clarify. The setting that Taylor Collison is speaking to ("other than refractory BCG, such as immediately following TURBT").... The first part of this bracketed statement hilited is not the same setting as being reported as all patients are BCG refractory in the trial being reported. Thus, not quite apples-to-apples but directionally positive as you will read below.
This was clarified for me (by BNC IR, per below which I posted this on Feb 7) after it was mentioned in the Q1 2012 shareholder letter, MDA (ASX site) re:
"At the 3rd European Multidisciplinary Meeting on Urological Cancers, held in Barcelona, Spain, in November, 2011, a sub-analysis of the first Phase III trial with Urocidin was presented..."
rg
To: Shea, Jennifer
Subject: Morning Jennifer...a question re Q1-12 Letter to Shareholders...
....Per the following quote in blue found on page 2 of the Letter...were the 16 patients in this sub-analysis BCG refractory? (with NMI bladder cancer)...or, prior to being treated with BCG i.e., at the initial step of diagnosis just after a TURBT is performed? If the latter, is this then speaking to Urocidin's "off-label" potential in NMI bladder cancer?
Hello,
These patients were BCG refractory. You are correct that this result speaks to a potential new use of Urocidin immediately post-TURBT. (resizing of text my addition)
Sincerely, Jennifer